Patents Assigned to Tcelltech Inc.
  • ANTI-B7-H3 MONOCLONAL ANTIBODY AND USE THEREOF IN CELL THERAPY
    Publication number: 20250051451
    Abstract: The present invention provides an anti-B7-H3 monoclonal antibody and use thereof in cell therapy. Specifically, the present invention provides an scFv, an antibody, and a specific CAR-T cell specifically targeting B7-H3. The present invention further provides an engineered immune cell capable of co-expressing a CAR targeting B7-H3 and a chimeric molecule or a secreted protein of PD-L1, the engineered immune cell having good tumor killing effects.
    Type: Application
    Filed: August 26, 2024
    Publication date: February 13, 2025
    Applicants: FUZHOU TCELLTECH BIOTECHNOLOGY CO., LTD., TCELLTECH INC.
    Inventors: Gangxiong HUANG, Liqun LUO
  • Anti-B7-H3 monoclonal antibody and use thereof in cell therapy
    Patent number: 12103973
    Abstract: The present invention provides an anti-B7-H3 monoclonal antibody and use thereof in cell therapy. Specifically, the present invention provides an scFv, an antibody, and a specific CAR-T cell specifically targeting B7-H3. The present invention further provides an engineered immune cell capable of co-expressing a CAR targeting B7-H3 and a chimeric molecule or a secreted protein of PD-L1, the engineered immune cell having good tumor killing effects.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: October 1, 2024
    Assignees: Fuzhou Tcelltech Biotechnology Co., Ltd., Tcelltech Inc.
    Inventors: Gangxiong Huang, Liqun Luo